List view / Grid view
Deal to advance potential first-in-class RNA therapeutics focused on genetic…
Deal to advance potential first-in-class RNA therapeutics focused on genetic neuromuscular diseases such as Duchenne muscular dystrophy.
Roche and Novartis agree on the repurchase by Roche Holding…
Roche and Novartis agree on the repurchase by Roche Holding Ltd of 53.3 million shares from Novartis worth 19 billion Swiss francs (CHF).
In a formal ceremony, the new headquarters for Novartis has…
In a formal ceremony, the new headquarters for Novartis has been opened in White City, London, in close proximity to Imperial College London’s research campus.
The pharmaceutical industry saw some notable mergers and acquisitions in…
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
A partnership between Novartis and NHS England includes a proposal…
A partnership between Novartis and NHS England includes a proposal to investigate processes that can increase the scale and efficacy of oligonucleotide manufacture.
The M&A between Novartis and The Medicines Company will add…
The M&A between Novartis and The Medicines Company will add inclisiran, the potentially first-in-class treatment to reduce cholesterol, to the former’s pipeline.
The global generic drugs market continues to grow. With increasing…
The global generic drugs market continues to grow. With increasing demand for more accessible medication, pharmaceutical companies are harnessing the benefits offered by generic drugs. Here are the top five generic drugs makers by revenue.
Novartis is to invest more than $ 100 million to…
Novartis is to invest more than $ 100 million to advance research and development of new antimalarials over the next five years...
A patient trial for KAF156, a next-generation antimalarial compound with…
A patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite has been launched...
